Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar;2(3):178-85.
doi: 10.18632/oncotarget.235.

IgH gene rearrangements as plasma biomarkers in Non- Hodgkin's lymphoma patients

Jian He  1 , Jian Wu, Yuchen Jiao, Nina Wagner-Johnston, Richard F Ambinder, Luis A Diaz Jr, Kenneth W Kinzler, Bert Vogelstein, Nickolas Papadopoulos
Affiliations

IgH gene rearrangements as plasma biomarkers in Non- Hodgkin's lymphoma patients

Jian He et al. Oncotarget. 2011 Mar.

Abstract

New biomarkers with improved accuracy could be helpful for monitoring disease in patients with Non-Hodgkin's lymphomas (NHL). Towards this end, we have explored the feasibility of identifying the sequence of rearranged IgH genes using next-generation sequencing, then using PCR to detect specific rearranged DNA fragments in patients' plasma. By capturing and sequencing the IgH genomic regions (IgCap), we were able to detect and precisely determine the sequence of rearranged IgH loci in the tumors of three NHL patients. Moreover, circulating rearranged DNA fragments could be identified in the plasma of all three patients. Even in cases wherein tumor biopsies were unavailable, we were able to use the IgH capture approach to identify rearranged DNA loci in the plasma of 8 of 14 patients. IgCap may enable a more informed management of selected patients with NHL and other B-cell malignancies in the future.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interests.

Figures

Figure 1
Figure 1. PCR amplification of Ig rearrangements in plasma
DNA was purified from either the plasma of patients or from normal cells of an unrelated patient (Con). MW, molecular weight markers, size indicated on left in base pairs (bp).
Figure 2
Figure 2. PCR amplification of Ig rearrangements in tumors and plasma
Two Ig rearrangements are shown for each patient sample. DNA was purified from either from the tumor and plasma of patients or from normal cells of an unrelated patient (Con). MW, molecular weight markers, size indicated on left in base pairs (bp).
See this image and copyright information in PMC

Comment in

References

    1. Sawyers CL. The cancer biomarker problem. Nature. 2008;452(7187):548–552. - PubMed
    1. Papadopoulos N, Kinzler KW, Vogelstein B. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat Biotech. 2006;24(8):985–95. - PubMed
    1. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer. 2002;2(3):210–219. - PubMed
    1. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta. 2007;1775(1):181–232. - PubMed
    1. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society Guidelines for the Early Detection of Cancer, 2005. CA Cancer J Clin. 2005;55(1):31–44. quiz 55-36. - PubMed

Publication types